DART sees success with Duchenne biomarker

Mass High Tech: The Journal of New England Technology

DART Therapeutics LLC, a biotech focused on finding therapies for Duchenne Muscular Dystrophy (DMD), a progressive and fatal neuromuscular disease for which there is no current treatment, has completed tests on a new biomarker intended to speed drug development by cutting the number of patients needed for new drug trials by half.